Follow The Filings

DMRA Damora Therapeutics Inc.

Health Care, filed as DAMORA THERAPEUTICS INC (COM NEW), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 Owner
  • Max 0.2%
  • $60M

Who owns this now

Largest portfolio weights among holders, up to 0.2% (Andreas Halvorsen, Viking Global Investors). Not free-float ownership.

  1. Andreas Halvorsen 0.17%

Who owns DMRA

Sorted by value, long equity only, as of 2026 Q2.

History
Andreas Halvorsen, Viking Global Investors 0.17% Hold 2,311,082 $60M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by DMRA's executives, directors and 10% owners in the last 12 months, from their Form 4s

All DMRA insider trades
  • $253K bought by 1 insider
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Jennifer Jarrett CEO
    Buy
    $253K 12,500 shares at $20.23 +2.5% to stake
    Traded Sep 25 Filed Sep 28
    ↗

Also filed in the last 12 months, not counted as buying or selling: 7 option exercises, 4 sales to cover taxes, and 3 stock grants.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
8-K 1.01,3.03,5.03,7.01,9.01 Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 5.02,9.01 Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 4.01,9.01 Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
10-K Filing Doc
8-K 2.02,5.03,7.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13D/A — Filing Doc
424B5 Filing Doc
8-K 1.01,9.01 Filing Doc
8-K 5.02,5.03,8.01,9.01 Filing Doc
424B5 Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Net income -$38.35M -$21.44M -$209.84M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $36.77M $16.84M $260.42M
Total non-current assets * $1.45M $0.293M $0.104M
Total assets $38.23M $17.13M $260.53M
Total current liabilities $5.83M $1.2M $20.07M
Total non-current liabilities * $66,000 $104,000 $81,000
Total equity $32.33M $15.83M $240.38M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$36.91M -$18.62M -$6.73M
Cash from investing $22.33M $11.65M -$17.37M
Cash from financing $2.88M — $266.84M
Net change in cash * -$11.7M — $242.74M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.